UroGen Pharma Ltd.

UroGen Pharma Ltd. is a biotechnology company focused on developing and commercializing solutions for urothelial and specialty cancers. Its key technology is RTGel, a proprietary reverse thermal gelation hydrogel that enables sustained release of therapeutics. The company's portfolio includes Mitomycin, a generic drug used off-label as adjuvant chemotherapy for low-grade non-muscle invasive bladder cancer (NMIBC) after trans-urethral resection; Zusduri, a sustained-release formulation of mitomycin for NMIBC; and Jelmyto for pyelocalyceal solutions. Lead product candidates are UGN-103 (phase 3 for intravesical solution) and UGN-104 (phase 3 for pyelocalyceal solution), targeting low-grade upper tract urothelial cancer and low-grade intermediate risk NMIBC. Additionally, UGN-301, UGN-301+UGN 201, and UGN-301+gemcitabine are in phase 1 trials for high-grade NMIBC.

UroGen Pharma Ltd. is listed on the Nasdaq Global Market (NasdaqGM) under the ticker symbol URGN. Its shares trade in United States Dollars (USD). The company is headquartered in Princeton, New Jersey, and operates primarily in the United States, though it has international collaborations.

UroGen Pharma operates in the Healthcare sector and is classified under the Biotechnology industry. As a biotechnology company, it focuses on researching, developing, and commercializing innovative therapies for urological cancers, particularly non-muscle invasive bladder cancer (NMIBC) and upper tract urothelial cancer. Its work involves leveraging its proprietary RTGel technology to create sustained-release formulations that improve treatment outcomes.

UroGen Pharma Ltd. is headquartered in Princeton, New Jersey, United States. The company primarily serves the U.S. market, as indicated by its listing on the Nasdaq and its focus on FDA-regulated products. It has a license agreement with Agenus Inc. to develop and commercialize products for urinary tract cancers via intravesical delivery, and a licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104, suggesting some international collaboration.

UroGen Pharma generates revenue through the commercialization of its approved products, such as Jelmyto and Zusduri, and potentially through licensing agreements. The company's business model centers on developing and marketing proprietary formulations of existing drugs using its RTGel technology to improve efficacy and patient compliance. It also has pipeline candidates in clinical trials, including UGN-103, UGN-104, and UGN-301, which may generate future revenue upon approval. Additionally, licensing agreements with partners like Agenus Inc. and medac provide potential milestone payments and royalties.